|By Business Wire||
|July 24, 2014 03:30 AM EDT||
Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today it has been granted CE mark certification for its innovative stented aortic bioprosthesis CROWN PRT, now commercially available in Europe.
In the treatment of aortic valve disease, the replacement of the native aortic valve with a stented bioprosthesis represents a standard technique to provide older patients with a performing and durable solution, while relieving them from the discomfort of lifelong oral anticoagulation therapy.
Built upon Sorin’s 45 years of experience in heart valve design and commitment to continuous innovation, CROWN PRT is the latest advancement in stented aortic bioprosthesis technology, featuring surgeon-friendly design, PRT technology, state-of-the-art hemodynamic and durability performance.
A further illustration of Sorin’s commitment to continuous innovation, CROWN PRT enables intuitive intraoperative handling through short rinse time, enhanced ease of implant through visible markers, as well as improved radiographic visualization through dedicated X-ray markers.
Research has demonstrated that phospholipids play a key role in the calcification process of bioprotheses and Sorin’s patented Phospholipid Reduction Treatment (PRT) has been shown to decrease phospholipid content in pericardial tissue thus leading to a remarkable reduction of calcium uptake compared to control1.
“We are eagerly looking forward to implanting CROWN PRT, as this valve incorporates all the latest technological advancements in a modern bioprosthesis, enabling cardiac surgery procedures that are simple, reliable and reproducible,” said Professor Alain Leguerrier, Chief of the Cardio Thoracic and Vascular Surgery Department, Centre Hospitalier Universitaire de Rennes, France. “CROWN PRT meets all the conditions for a remarkable hemodynamic performance and an optimized durability.”
“CROWN PRT promises to further advance our presence in tissue valve segments in Europe and globally. This new innovation for heart valve replacement is strategically designed to provide physicians with greater surgical versatility as well as outstanding durability, reinforcing Sorin’s brand promise to deliver industry-leading technologies in cardiac surgery,” said Michel Darnaud, President, Cardiac Surgery Business Unit, Sorin Group.
About Sorin Group
Sorin Group (www.sorin.com) is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose arrhythmias and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.
For more information, please visit www.sorin.com
1 Based on 60-day animal model. Sorin Group 2014. Data on file.
Aug. 26, 2016 05:00 AM EDT Reads: 3,011
Aug. 26, 2016 03:15 AM EDT Reads: 1,399
Aug. 26, 2016 02:15 AM EDT Reads: 1,940
Aug. 26, 2016 01:30 AM EDT Reads: 1,663
Aug. 26, 2016 01:15 AM EDT Reads: 2,007
Aug. 26, 2016 01:00 AM EDT Reads: 1,947
Aug. 26, 2016 12:45 AM EDT Reads: 2,249
Aug. 26, 2016 12:30 AM EDT Reads: 2,897
Aug. 25, 2016 11:45 PM EDT Reads: 2,284
Aug. 25, 2016 10:45 PM EDT Reads: 1,868
Aug. 25, 2016 10:15 PM EDT Reads: 1,715
Aug. 25, 2016 09:15 PM EDT Reads: 2,202
Aug. 25, 2016 09:00 PM EDT Reads: 1,700
Aug. 25, 2016 06:30 PM EDT Reads: 1,936
Aug. 25, 2016 05:15 PM EDT Reads: 697